12-14-5　ⓔ文献

  1. Mocchegiani F, Vincenzi P, et al: Prevalence and clinical outcome of hepatic haemangioma with specific reference to the risk of rupture: a large retrospective cross–sectional study. Dig Liver Dis, 2016; 48: 309–314.

  2. Glinkova V, Shevah O, et al: Hepatic haemangiomas: possible association with female sex hormones. Gut, 2004; 53: 1352–1355.

  3. Boye E, Yu Y, et al: Clonality and altered behavior of endothelial cells from hemangiomas. J Clin Invest, 2001; 107: 745–752.

  4. 日本医学放射線学会および日本放射線科専門医会・医会共同編集：肝海綿状血管腫の画像診断ガイドライン2007年版，2007.

  5. Rooks JB, Ory HW, et al: The role of oral contraceptive use. JAMA, 1979; 242: 644–648.

  6. WHO Classification of Tumours Editorial Board: Digestive system tumours. WHO Classification of Tumours 5th Edition, WHO Press, 2019.

  7. Wanless IR, Mawdsley C, et al: On the pathogenesis of focal nodular hyperplasia of the liver. Hepatology, 1985; 5: 1194–1200.

  8. Bioulac–Sage P, Cubel G, et al: Revisiting the pathology of resected benign hepatocellular nodules using new immunohistochemical markers. Semin Liver Dis, 2011; 31: 91–103.

  9. Sato Y, Harada K, et al: Hepatic stellate cells are activated around central scars of focal nodular hyperplasia of the liver: a potential mechanism of central scar formation. Hum Pathol, 2009; 40: 181–188.